Agilent TechnologiesFRA:AG8 +0.31%94 Days Payable is 65.56 as of Apr. 2026, which is 23% above its 10-year median of 53.20. GuruFocus rates FRA:AG8 with a GF Score™ of 94/100 and a GF Value™ of €127.15 (Modestly Undervalued). The stock has 1 warning sign investors should review. Among 192 Medical Diagnostics & Research companies, Agilent Technologies ranks worse than 54.17% on this metric.
The historical rank and industry rank for Agilent Technologies's Days Payable or its related term are showing as below:
FRA:AG8'
s Days Payable Range Over the Past 10 Years
Min: 48.79 Med: 53.2 Max: 61.29
Current: 60.53
During the past 13 years, Agilent Technologies's highest Days Payable was 61.29. The lowest was 48.79. And the median was 53.20.
FRA:AG8's Days Payable is ranked worse than 54.17% of 192
companies
in the Medical Diagnostics & Research industry
Industry Median: 65.385
vs FRA:AG8: 60.53
Agilent Technologies's Days Payable
increased
from Apr. 2025 (63.19) to Apr. 2026 (65.56).
It may suggest that Agilent Technologiesdelayed paying its suppliers.
Agilent Technologies Days Payable Related Terms
Agilent Technologies Days Payable Historical Data
* Premium members only.
The historical data trend for Agilent Technologies's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:AG8 vs NTRA, WAT, IDXX: Days Payable Comparison
For the Diagnostics & Research subindustry, Agilent Technologies's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Agilent Technologies Days Payable vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Agilent Technologies's Days Payable distribution charts can be found below:
* The bar in red indicates where Agilent Technologies's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Agilent Technologies's Days Payable for the fiscal year that ended in Oct. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Agilent Technologies (FRA:AG8) has a Days Payable of 65.56 as of Apr. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Agilent Technologies and its competitors. This is 23% above median its historical median of 53.20. Over the past decade, Agilent Technologies' Days Payable has ranged from 48.79 to 61.29. According to the industry distribution chart, Agilent Technologies ranks #104 out of 192 companies in the Medical Diagnostics & Research industry, placing it in the top 54.2%.
Is Agilent Technologies' Days Payable too high?
Agilent Technologies' current Days Payable of 65.56 is 23% above median its 10-year median of 53.20. Over the past 10 years, this metric has ranged from a low of 48.79 to a high of 61.29. The Medical Diagnostics & Research industry median Days Payable is 65.39. Agilent Technologies' value of 65.56 is 0.3% above this industry median. Based on the distribution chart, Agilent Technologies ranks #104 out of 192 companies in the Medical Diagnostics & Research industry, which is below the industry midpoint. Overall, Agilent Technologies has a GF Score™ of 94/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Agilent Technologies' Days Payable compare to NTRA and WAT?
According to the Medical Diagnostics & Research industry distribution chart, Agilent Technologies ranks #104 out of 192 companies for Days Payable. This places Agilent Technologies in the lower half of its industry. The industry median Days Payable is 65.39. Agilent Technologies' value of 65.56 is 0.3% above this benchmark. Historically, Agilent Technologies' own Days Payable has ranged from 48.79 to 61.29 over the past decade. While the company's 10-year median is 53.20 vs. the industry median of 65.39, Agilent Technologies has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Medical Diagnostics & Research company?
The median Days Payable among Medical Diagnostics & Research companies is 65.39, based on 192 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Agilent Technologies's current Days Payable of 65.56 is 0.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Agilent Technologies and its competitors. For the Medical Diagnostics & Research industry, the median Days Payable is 65.39 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Agilent Technologies's current Days Payable is 65.56, which is 23% above median its own 10-year median of 53.20. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Agilent Technologies stock overvalued right now?
Based on GuruFocus' analysis, Agilent Technologies (FRA:AG8) is currently considered Modestly Undervalued. The stock's GF Value™ is €127.15, compared to a current price of €114.00 — trading 10.3% below its estimated fair value. The current Days Payable is 65.56, which is 23% above median its 10-year median of 53.20 and 0.3% above the Medical Diagnostics & Research industry median of 65.39. Agilent Technologies' overall GF Score™ is 94/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Agilent Technologies (FRA:AG8), the current Days Payable is 65.56 as of Apr. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Agilent Technologies (FRA:AG8) Overvalued in 2026?
Based on GuruFocus' analysis, Agilent Technologies stock appears to be undervalued.
The current stock price of €114.00 is trading 10.3% below its estimated GF Value™ of €127.15.
GuruFocus considers Agilent Technologies to be Modestly Undervalued.
Key valuation signals for FRA:AG8:
Days Payable: 65.56 (23% above median its 10-year median of 53.20)
GF Value™: €127.15 vs. price of €114.00 (10.3% below fair value)
Industry Position: 0.3% above the Medical Diagnostics & Research median (#104 of 192)
No single metric tells the full story. See the FRA:AG8 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Originally spun out of Hewlett-Packard in 1999, Agilent has evolved into a leading life science and diagnostic firm. Today, Agilent's measurement technologies serve a broad base of customers with its three operating segments: life science and diagnostics, cross lab operations consisting of consumables and services, and applied end markets. Over half of its sales are generated from the biopharmaceutical, chemical, and advanced materials end markets, which we view as the stickiest end markets, but it also supports clinical lab, environmental, forensics, food, academic, and government-related organizations. The company is geographically diverse, with operations in the US and China representing the largest country concentrations.
94GF Score
Get the complete analysis for FRA:AG8
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:AG8 has been successfully added to your 
